Acquisition of Synergy Pharmaceuticals is expected to expand Bausch Health’s gastroenterology portfolio. Credit: PRNewsfoto/Bausch Health Companies Inc.

Canada-based Bausch Health Companies has won a bid to acquire certain assets of US-based biopharmaceutical firm Synergy Pharmaceuticals for a cash consideration of $195m.

The terms of the deal also include the assumption of selected assumed liabilities, pursuant to the stalking horse agreement signed by Bausch Health and Synergy.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Synergy Pharmaceuticals is engaged in the development and commercialisation of new treatment options for patients suffering from gastrointestinal (GI) therapies.

The company filed a voluntary petition for bankruptcy under Chapter 11 of the US Code in December last year.

Bausch Health then entered a definitive agreement to buy select Synergy Pharmaceuticals assets. The Canadian company served as the ‘stalking horse’ bidder in a court-supervised auction and sale process.

Synergy Pharmaceuticals found Bausch Health’s offer to be the highest and best bid for its assets. Bausch Health expects the acquisition to boost its Salix Pharmaceuticals business focused on GI diseases.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“With our team’s expertise in GI and primary care, we will strengthen our already formidable portfolio of innovative irritable bowel syndrome solutions with the addition of Trulance.”

Bausch Health chairman and CEO Joseph Papa said: “We are excited to acquire the assets of Synergy, which we believe will strategically enhance our Salix Pharmaceuticals business and supplement our organic growth in gastroenterology.

“With our team’s expertise in GI and primary care, we will strengthen our already formidable portfolio of innovative irritable bowel syndrome solutions with the addition of Trulance.”

Synergy’s Trulance is a once-daily medicine indicated for adults with chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C).

Its investigational incremental peptide dolcanatide will also be added to Bausch Health’s pipeline.

Bausch Health develops, manufactures and markets pharmaceutical, medical device and over-the-counter products across gastroenterology, eye health and dermatology areas.